Abstract ADAMTS13 mRNA, which encodes the von Willebrand factor-cleaving protease, has been detected in a variety of tissues, including the kidney. The aim of our study was to characterize tubular expression and bioactivity of ADAMTS13. ADAMTS13 mRNA was detected in cultured primary human renal tubular epithelial cells (HRTEC) and in A498 cells, a human renal carcinoma cell line, by real-time PCR. Protein was detected using immunofluorescence and immunoblotting. Immunoblots demonstrated that the protein was secreted. The protease was proteolytically active in both cell lysates and cleaved the FRETS-VWF73 substrate. ADAMTS13 was demonstrated in situ in the renal cortex by immunohistochemistry. Protease was detected in both the proximal and distal renal tubules in normal renal tissue (n=3) as well as in patients with tubular disorders (n=3). Immunoblotting revealed that ADAMTS13 was present in the urine of patients with tubulopathy (n=5) but not in normal urine. ADAMTS13 in urine had a molecular size similar to that in plasma, which indicates that the protease originates in the tubuli because such large proteins do not normally pass the glomerular filter. In conclusion, human renal tubular epithelial cells synthesize biologically active ADAMTS13 which may, after release from tubuli, regulate hemostasis in the local microenvironment.
Introduction
ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type-1 motifs) is the physiological von Willebrand factor (VWF) cleaving protease [1, 2] . Severe ADAMTS13 deficiency (<5% of normal plasma activity) is associated with thrombotic thrombocytopenic purpura (TTP) [3] and may occur due to mutations in the ADAMTS13 gene (congenital TTP) [4, 5] or to autoantibodies against the protease (acquired TTP) [6] .
TTP is a thrombotic microangiopathy characterized by the occurrence of disseminated VWF and platelet-rich thrombi in the microcirculation of multiple organs, including the kidneys [7, 8] . The function of VWF is to induce the formation of platelet thrombi at sites of vascular injury and high-shear stress. This function is dependent on the size of the VWF multimers, i.e. the larger the VWF multimer, the more biologically active it is in inducing platelet aggregation. ADAMTS13 regulates the size and thereby the activity of VWF multimers through rapid cleavage upon their release from endothelial cells [9] . Deficient VWF cleavage, as occurs in TTP, allows ultra-large VWF (ULVWF) to accumulate in the circulation and contribute to thrombus formation [10] .
ADAMTS13 normally circulates in plasma and has a mass of approximately 150 kDa under non-reducing conditions and 190 kDa under reducing conditions [1, 11] . ADAMTS13 antigen is present in the plasma of patients with acquired TTP, where it appears to be in complex with auto-antibodies [12] , and is absent in those with congenital TTP [11, 13] . The cellular origin of ADAMTS13 antigen in plasma has not been completely elucidated but the protease has been shown to be synthesized in liver stellate cells and in endothelial cells [14, 15] . ADAMTS13 mRNA has been detected in a variety of tissues, including the kidneys [4, 16, 17] . The kidney is one of the organs mainly affected in TTP, and the localization of renal ADAMTS13 expression may therefore be relevant for an understanding of the pathophysiology of this disease. In a previous study, we demonstrated ADAMTS13 expression in the renal cortex in podocytes, glomerular endothelium, basement membrane, and tubuli [16] .
The ADAMTS13 protease has been well characterized and consists of a signal peptide, a short propeptide, the metalloprotease domain, a disintegrin-like domain, a thrombospondin-1 repeat, a Cys-rich domain, a spacer domain, seven additional thrombospondin-1 (TSP-1) repeats, and two CUB domains [2] . In the study reported here we characterized ADAMTS13 expression in cultured renal tubular epithelial cells by real-time PCR, immunoblotting, and immunofluorescence using monoclonal and polyclonal antibodies directed to distinct domains in the protease. Bioactivity was demonstrated using the FRETS-VWF73 assay. In situ tubular cell expression was studied by immunohistochemistry, and the pattern of expression in tubular damage as well as secretion into the tubular lumen and, ultimately, into urine was investigated.
Methods and subjects
Cell culture ADAMTS13 expression was investigated in two cultured cell types of proximal tubular origin: (1) human renal tubular epithelial cells (HRTEC), which are primary human renal cortical cells originally isolated in our laboratory and characterized as tubular epithelial cells [18] ; (2) the A498 cell line, which originates from human renal epithelial carcinoma of tubular origin [19] . HRTEC and A498 cells were cultured as previously described [18, 20] . Briefly, HRTEC were grown in the Advanced D-MEM F-12 medium (Invitrogen, Karlsruhe, Germany) supplemented with 20 U/ml heparin (Leo Pharma, Malmö, Sweden), 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 15% fetal bovine serum (all from Invitrogen). A498 cells were cultured in RPMI-1640 medium (Sigma-Aldrich Chemie, Steinheim, Germany) supplemented with 1 mM non-essential amino acids (PAA Laboratories, Cölbe, Germany), 1 mM sodium pyruvate (PAA Laboratories GmbH), 100 U/ml penicillin, 100 μg/ml streptomycin, and 10% fetal bovine serum (all from Invitrogen). Cells were grown in culture flasks (Göteborgs Termometerfabrik, Västra Frölunda, Sweden) to collect cell lysate, medium and RNA, or on chamber slides (Nunc, Roskilde, Denmark) for immunofluorescence staining. HRTEC were used at passage 3-4. For experiments, cells at approximately 95% confluence were washed and incubated with serum-free medium (as above for each cell type but without serum). After 24 h, media were collected and supplemented with the Complete EDTA-free protease inhibitors (Complete Mini, EDTA-free; Roche Diagnostics, Mannheim, Germany). The media were centrifuged to remove cell debris and concentrated 20-to 30-fold using Centricon concentrators (Millipore, Bedford, MA). The cells were washed and trypsinized. Detached cells were washed and lyzed in lysis buffer (0.01 M Tris, 0.15 M NaCl, pH 7.4) supplemented with protease inhibitors. Approximately 0.7-1×10 6 cells/100 μl buffer were lyzed by repeated freezing and thawing (in liquid nitrogen and 37°C water bath, respectively) followed by sonication in an ultrasonic bath [Grants Instruments (Cambridge), Royston, UK]. Cell debris was removed by centrifugation. Total RNA was isolated as previously described [16] . For the immunofluorescence experiments, cells grown on chamber slides were washed, fixed with 2% paraformaldehyde (Sigma Aldrich Chemie), 4% sucrose (Acros, Geel, Belgium) in PBS, and permeabilized with 0.3% Triton X-100 (ICN Biomedical, Aurora, OH) in PBS, as previously described [21] .
Real-time PCR
RNA was reverse transcribed and ADAMTS13 gene transcripts were detected by real-time PCR (ABI Prism 7000; Applied Biosystems, Foster City, CA) with a probe against exons 28-29 (translating into part of the second CUB domain; Applied Biosystems, assay ID Hs00260148_m1) [16] . We have previously shown that kidney contains ADAMTS13 mRNA [16] ; therefore, normal kidney RNA pooled from 14 individuals (BD Biosciences Clontech, Palo Alto, CA) was used as the positive control. Normal liver RNA (BD Biosciences) was also used as a positive control. No template control was used as the negative control. The 18S ribosomal RNA transcript (Applied Biosystems, assay ID Hs99999901_s1) was used as the reference gene to standardize the data.
Anti-ADAMTS13 antibodies
Two polyclonal rabbit anti-human ADAMTS13 antibodies generated in our laboratory were used: (1) SU19 against the second CUB domain, as previously described [11] ; (2) SNO357 directed against the metalloprotease and disintegrin-like domains, specifically at amino acids 281-296 of the protease. The peptides against which these antibodies were raised were synthesized by Eurogentec, Seraing, Belgium. We also used one mouse monoclonal antibody, A10 (a gift from Y. Fujimura, Department of Blood Transfusion Medicine, Nara Medical University, Nara and H. Hiura, Japan Clinical Laboratories, Kyoto, Japan), directed against the disintegrin-like domain [14] . The SU19 polyclonal antibody recognizes ADAMTS13 under reducing and non-reducing conditions [11] , whereas the SNO357 antibody recognizes ADAMTS13 only under reducing conditions and the A10 antibody recognizes only the non-reduced form [11] .
Immunofluorescence ADAMTS13 was detected using the A10 monoclonal antibody at 5 μg/ml or SU19 polyclonal anti-ADAMTS13 F(ab′) 2 at 15 μg/ml, as previously described [16] . The signal was detected using goat-anti-mouse IgG F(ab') 2 FITC 1:20 (Dako Cytomation, Carpinteria, CA) or goat-anti-rabbit (H+L) F(ab') 2 Alexa Fluor 488 1:150 (Molecular Probes, Invitrogen). Normal mouse IgG 2bÀk was used as the isotype control antibody for A10. Specificity of the polyclonal antibody was tested by preincubation with a 50-fold molar surplus of blocking peptide [16] . Specificity of the secondary antibodies was tested by omitting the primary antibody.
Immunoblotting for detection of ADAMTS13
HRTEC and A498 cell lysates and media (1:2) were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting under reducing conditions, as previously described [11] . ADAMTS13 was detected with the SNO357 antibody at 3.6 μg/ml. Purified recombinant ADAMTS13 1:2 was used as the positive control. For this purpose, we cultured HEK293 cells transfected with the pIRESneo2 VCP HIS-vector containing the human ADAMTS13 gene (a kind gift from Professor Reinhard Schneppenheim, University Medical Center Hamburg-Eppendorf, Department of Pediatric Hematology and Oncology, Hamburg, Germany). The His-tagged protease was purified from HEK293 cell medium on Ni Sepharose His SpinTrap columns (GE Healthcare, Buckinghamshire, UK). Specificity of the antibody was tested by preincubation with 50-fold molar surplus of blocking peptide prior to the immunoblotting procedure, as previously described [11] .
Urine samples were subjected to SDS-PAGE and immunoblotting as previously described [11] . Samples were concentrated 20-fold with Centricon concentrators (Millipore). Immunoblotting with samples diluted 1:2 under non-reducing conditions was carried out using the A10 (0.55 μg/ml) monoclonal antibody. Normal plasma was used as the positive control.
VWF-cleaving activity ADAMTS13 VWF-cleaving activity in HRTEC and A498 cell lysates was assayed using the FRETS-VWF73 substrate as previously described [22] . Briefly, 10 μl of sample was added to each well, followed by the addition of 100 μl each of assay buffer (5 mmol/l Bis-Tris, 25 mmol/l CaCl 2 , 0.005% Tween-20, pH6.0) and substrate solution (2 μM final concentration of FRETS-VWF73) [22] . A dilution series of normal pooled plasma was used to calibrate the assay. Lysis buffer was used as the negative control. In order to test specificity, cell lysates were preincubated with the A10 monoclonal antibody at 50 μg/ml final concentration, which has previously been shown to block ADAMTS13 activity [14] .
Immunohistochemistry
Renal tissue was formaldehyde-fixed, paraffin-embedded, sectioned (3.5 μm on glass slides), and prepared as previously described [23] . ADAMTS13 expression in renal tissue was detected by immunohistochemistry with the A10 monoclonal antibody at 3 μg/ml as previously described [16] . The signal was detected using EnVision+ System anti-mouse horseradish peroxidase (HRP; Dako Cytomation). Normal mouse IgG 2bÀk was used as the isotype control, and the specificity of the secondary antibody was tested by omission of the primary antibody. Positive signal stained brown.
Urine samples and renal tissue from patients and controls

Patients
Urine samples were available from five patients and renal biopsies from three patients with tubular disorders. All patients were being treated at the Division of Pediatric Nephrology of the Department of Pediatrics, Lund University Hospital. These patients are described in Table 1 . Sufficient renal tissue for immunohistochemical analysis was available from patients 4, 5, and 6.
Controls
Positive controls for the presence of ADAMTS13 in urine Urine from a 16-year old female patient with nephrotic syndrome was available for analysis. The patient had nephrotic syndrome (with nephrotic-range proteinuria at sampling) due to focal segmental glomerulosclerosis, as diagnosed by renal biopsy in which no tubular damage was detected.
Urine from a 3-year old girl with acute post-infectious glomerulonephritis was also available. The diagnosis was based on the simultaneous presence of macroscopic hematuria, hypertension, and low complement C3. At debut of symptoms, the patient had non-nephrotic range albuminuria, as detected by albumin/creatinine index of 116 (reference value <3.8 g/mol). No evidence of streptococcal infection was found, and the patient made a full recovery, including normalization of complement levels.
Pediatric controls for ADAMTS13 in urine Urine samples were available from four pediatric controls treated at the outpatient clinic of the Division of Pediatric Nephrology, Department of Pediatrics, Lund University Hospital. These patients, all boys aged 3, 6, 8, and 16 years, were followed for reflux nephropathy (two patients), posterior urethral valve, and hypertension, respectively.
Normal controls Urine samples from seven healthy adults (of which three were women) were used as normal controls. None of the negative controls, both healthy adults and pediatric controls, had glomerular or tubular proteinuria (assayed as in Table 1 ).
Control renal tissue was obtained from two adult patients (one male and one female) nephrectomized due to renal cancer. The tissue was taken from areas unaffected by the cancer and deemed to be normal by the pathologist. The patients had not received chemotherapy or radiotherapy prior to surgery. Normal renal tissue was also obtained from a renal biopsy taken from a 10-year old girl investigated for hematuria in which the renal biopsy was assessed to be normal based on light microscopy examination and immunofluorescence [23] . The study was conducted with the approval of the ethics committee of Lund University, and samples were taken with the informed written consent of the participants or their parents.
Results
ADAMTS13 mRNA is expressed in cultured tubular epithelial cells
ADAMTS13 mRNA was detected in HRTEC and A498 cells using the probe against exons 28-29. The human liver and kidney have been shown to express ADAMTS13 mRNA [4, 16, 17] and were therefore used as the positive controls. The negative control (no template control) showed no amplification (data not shown). The housekeeping gene 18S was expressed at comparable levels in all samples (data not shown) and was used as an endogenous control to standardize the data. Results are presented as the ratio of ADAMTS13/ 18S (Fig. 1). ADAMTS13 protein is expressed in cultured tubular epithelial cells ADAMTS13 expression was detected in primary HRTEC cells (Fig. 2, upper panel) using the A10 monoclonal antibody against the disintegrin-like domain and the SU19 polyclonal antibody against the second CUB domain of the protease, respectively (Fig. 2a, b) . There was no signal when HRTEC were incubated with the mouse control antibody (Fig. 2c) , while preincubation of the polyclonal antibody with blocking peptide markedly reduced staining (Fig. 2d) . No signal was detected when the primary antibodies were omitted (Fig. 2e, f) . The renal carcinoma A498 cell line showed similar results (Fig. 2, lower panel) . ADAMTS13 expression was observed using both the monoclonal and polyclonal antibody (Fig. 2g,  h) . Specificity experiments were carried out as for HRTEC and resulted in similar observations (Fig. 2i-l) .
ADAMTS13 expression was further investigated by immunoblotting of the cell lysates and media. Purified recombinant human ADAMTS13 was used as the positive control and exhibited a band at 190 kDa under reducing conditions using the SNO357 antibody against the metalloprotease/disintegrin-like domains (Fig. 3) . Immunoblots of HRTEC cell lysates and media revealed bands at approximately 170 and 150 kDa, respectively (Fig. 3) . Preincubation of the antibody with the blocking peptide which it was raised against, prior to the immunoblotting procedure, resulted in the elimination of all bands (data not shown). No bands were detected in the cell lysates and media of A498 cells (data not shown).
ADAMTS13 activity
The test performed to determine whether cultured HRTEC and A498 cells had the ability to cleave the FRETS-VWF73 substrate revealed VWF-cleaving activity in both cell types (Fig. 4) . The HRTEC and A498 cell lysates showed a mean activity value of 6.24% (range 4.90-9.16%) and 10.12% (range 6.05-13.50%), respectively. To test the specificity of the assay, we incubated the HRTEC and A498 lysates with the A10 monoclonal antibody, which has been shown to inhibit ADAMTS13 activity [14] , and found that the activity values fell to 1.93 and 3.44%, respectively.
ADAMTS13 expression in damaged renal tubuli
The expression pattern of ADAMTS13 was examined in normal renal tissue as well as in biopsies from patients 4, 5, and 6, who had tubular damage. ADAMTS13 antigen expression was detected in all tubular cells of the renal cortex, suggesting its presence in both proximal and distal tubuli (Fig. 5a, normal renal tissue; Fig. 5b, tissue from patient 4 ). ADAMTS13 showed a diffuse intracellular expression pattern in the normal tissue (Fig. 5c ), while in renal tissue from patients 4 and 5, it was either expressed diffusely or concentrated apically in damaged tubular cells (Fig. 5d, e) . The tissue from patient 4 also showed desquamated tubular epithelial cells containing ADAMTS13 (Fig. 5e) . Labeling of the renal biopsy from patient 6 showed similar results (data not shown). The control antibody did not exhibit staining (Fig. 5f ). Similarly, experiments in which the primary antibody was omitted were negative (data not shown).
ADAMTS13 detection in urine samples
Urine samples were investigated for ADAMTS13 expression with the A10 monoclonal antibody using the immunoblotting procedure under non-reducing conditions. The results are shown in Fig. 6 . ADAMTS13 was not detected in the urine from the seven healthy individuals (Fig. 6 , lane 1 shows urine from one normal control) or in the urine samples from the four pediatric controls (data not shown). The A10 monoclonal antibody has previously been shown to detect an ADAMTS13 band in plasma at 150 kDa [11] . Using normal plasma as the positive control, we also found a strong immunoreactive band at 150 kDa (Fig. 6, lane 2) . Urine from the two positive controls (with unselective proteinuria) were run for comparison and also exhibited a strong immunoreactive band at 150 kDa (urine from the patient with nephrotic syndrome is shown in Fig. 6 , lane 3; data not shown for the other patient). An immunoreactive band at approximately 150 kDa was observed in the urine samples from patients 1-5 who had tubular damage (Fig. 6, lanes 4-8) .
Discussion
In the kidney, ADAMTS13 is found in glomerular endothelial cells, podocytes, the glomerular basement following the incubation of A498 cells with the A10 monoclonal antibody and the SU19 polyclonal antibody, respectively (g, h), while there was no signal following incubation with the mouse control antibody (i). Blocking of the polyclonal antibody with the peptide it was raised against resulted in marked decrease in signal intensity (j).
No signal was obtained when the primary antibodies were omitted (k, l). Reproducible results were obtained in at least three experiments performed on slides coated with cells from two separate experiments with each cell type. All images are at 600× magnification membrane, and in tubular epithelial cells [16] . We have investigated ADAMTS13 expression and activity in renal tubular epithelial cells. Both primary HRTEC and a renal carcinoma cell line of tubular epithelial origin (A498) [19] expressed ADAMTS13 mRNA (detected by real-time PCR) and protein (detected by immunofluorescence and immunoblotting). Furthermore, ADAMTS13 expressed by both cell types showed biological activity and was able to cleave the FRETS-VWF73 substrate [22] . ADAMTS13 was detected in the renal cortex in tubuli where it showed a diffuse staining pattern in normal renal tissue and a diffuse staining pattern or apical accumulation in renal tissue from patients with tubular damage. ADAMTS13 was also detected in the urine of patients with tubular damage but not in that of normal individuals. Taken together, these results indicate that tubular cells synthesize biologically active ADAMTS13. Urine samples from patients with tubular damage subjected to immunoblotting revealed detectable ADAMTS13. The size of the ADAMTS13 band detected in these urine samples was comparable to that in the plasma, indicating that tubular cells are capable of synthesizing and secreting full-length ADAMTS13. No ADAMTS13 was detected in the urine from the normal adult controls or from that of four pediatric controls. Such a large protein would not be expected to be filtered into the urine of individuals with healthy glomeruli, explaining why it is not found in normal urine. Its presence in patients with tubular injury suggests that ADAMTS13 originated from the tubular cells as this large protein (150 kDa) should not normally pass the glomerular barrier. Albumin (66 kDa) and low-molecular-weight proteins may be filtered in small amounts, but they undergo reabsorption in healthy tubular cells. The presence of minimal albuminuria in patients with tubulopathy is indicative of defective tubular reabsorption. The ADAMTS13 band was much stronger in the positive controls with nephrotic syndrome and post-infectious glomerulonephritis due to the fact that these patients leak plasma proteins unselectively into the urine.
ADAMTS13 VWF-cleaving activity was measured in the cell lysates as the ability to cleave the FRETS-VWF73 peptide, which is the smallest known substrate for ADAMTS13 [22, 24] . Activity was detected in both cell types and was markedly decreased when the cell lysates were preincubated with an inhibitory antibody, further indicating specific ADAMTS13 activity. The presence of ADAMTS13 in the medium of HRTEC cells suggests that the protease is secreted from tubular cells. ADAMTS13 was not detected in the medium and lysates of A498 cells. This discrepancy between HRTEC and A498 cells may be attributed to the fact that HRTEC are primary cells, thereby more closely resembling normal cell physiological conditions, whereas the A498 is a cell line. Analysis of the HRTEC medium and lysate revealed a band at 150 and 170 kDa, respectively. An ADAMTS13 band at 170 kDa has previously been described in endothelial cell lysates [25] , and the slightly lower band detected in the medium may represent a breakdown product. .12% (range 6.05-13.50%), respectively. Experiments were carried out twice using cells from two separate experiments with each cell type. Normal plasma was used as the reference standard. The specificity of the assay was tested by preincubation with the A10 monoclonal antibody [29] , which has been shown to inhibit ADAMTS13 activity [14] . Activity values decreased to a mean of 1. Immunohistochemical studies of normal renal cortex showed that ADAMTS13 is diffusely expressed in renal tubular cells. However, in the renal tissue from patients with tubular damage, the ADAMTS13 antigen was also detected apically in the cells. It is as yet unclear if there is a shift in the localization of ADAMTS13 in damaged tubular cells and whether this is due to a passive mechanism as a result of damage to the tubular cells, or to an active one by which ADAMTS13 is transported to the lumen. This remains to be elucidated in future studies. Furthermore, desquamated tubular cells containing ADAMTS13 were found in patient tissue. We propose that the ADAMTS13 In addition to their role in regulating water and electrolyte balance, renal tubular cells seem to possess an important function in regulating coagulation/thrombosis and fibrinolysis in the kidney, as indicated by their ability to express a variety of proteins involved in these systems. Tubular epithelial cells have been shown to express both protein C and protein C inhibitor [26, 27] , tissue factor and tissue factor inhibitor [28, 29] as well as urokinase-type plasminogen activator [30] . Chronic or acute kidney disease characterized by tubular and interstitial damage, such as ischemic tubular necrosis and experimental lupus nephritis, are often associated with fibrin deposition in the peritubular capillaries and along the tubular basement membrane [29] . An analysis of protein C expression in kidneys from mice with lupus nephritis revealed decreased levels of protein C mRNA in renal tubuli, and lipopolysaccharide injected intraperitoneally in healthy mice led to a transient decrease in protein C mRNA in tubular epithelial cells [27] . Furthermore, Sappino et al. [30] demonstrated that murine tubular epithelial cells produced urokinase-type plasminogen activator that, besides its function in fibrinolysis, participated in extracellular proteolysis in tissue remodeling and cellular invasion. It is possible that ADAMTS13 expression by tubular epithelial cells may play a part in the regulation of hemostasis; however, recent studies have shown that tubular cells also produce and release matrix metalloproteinases, and their inhibitors, found to be active in tissue remodeling [31] . Thus, ADAMTS13 may have an alternate function, other than cleavage of VWF, possibly related to glomerular or tubular remodeling.
In a previous study [16] we demonstrated ADAMTS13 expression in podocytes and glomerular endothelial cells. The podocytes were found to secrete bioactive protease. We suggested that podocyte-derived ADAMTS13 may provide a mechanism by which secretion of the protease into the glomerular basement membrane protects glomeruli from the formation of platelet thrombi under local conditions of high shear stress and endothelial cell injury. We speculate that tubular cells could possibly secrete ADAMTS13 basally into peritubular capillaries, thereby providing a local protective mechanism against the formation of thrombi.
The findings observed in our study indicate that tubular epithelial cells are able to express proteolytically active ADAMTS13. Immunohistochemical studies of ADAMTS13 protein expression in situ in renal tubuli revealed that the pattern of expression may be altered with apical concentration in renal tissue from patients with tubular damage as compared to a more diffuse expression in normal tissue. In patients with tubular damage, ADAMTS13 is released into the urine. Thus, tubuli synthesize biologically functional ADAMTS13, possibly regulating hemostasis in the local vascular microenvironment. 
